Novo Nordisk is investing around DKK 750 million ($130 million) in new laboratories at the firm's R&D campus in Måløv, Denmark. Construction is already underway for the new facility, dubbed Diabetes Research House, which Novo Nordisk says will accommodate around 350 employees and should be ready for occupation in early 2016. The firm also expects the project to generate over 1,000 jobs outside Novo Nordisk during the construction phase.
With floor space of 16,500 square meters distributed on three stories, Diabetes Research House will have two laboratory wings, a middle building with office space, and an auditorium seating 450 people. Mads Krogsgaard Thomsen, Ph.D., Novo Nordisk's evp and CSO, said in a statement that the facility will provide an environment for diabetes research within biotechnology and protein chemistry.
“Here [at the facility] our researchers will be working closely together with leading scientists in Denmark and abroad on the discovery and development of new medicines for the treatment of type 1 and type 2 diabetes,” Dr. Thomsen commented.
The Danish firm is expanding in other parts of the world, too: In September it announced plans to establish a new obesity research unit in Seattle, WA. That announcement came a little over a week after the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 14–1 to recommend approval of Novo Nordisk's obesity candidate Saxenda for chronic weight management in adults with obesity or overweight with comorbidities, as an adjunct to diet and exercise.